Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 17/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723816 | 0.91 | CSF1R (0.56) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2726945 | 0.89 | CSF1R (0.57) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2723463 | 0.89 | CSF1R (0.57) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2725146 | 0.87 | CSF1R (0.57) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2726227 | 0.85 | CSF1R (0.58) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2723613 | 0.84 | CSF1R (0.63) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2725497 | 0.83 | KDM4E (0.54) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2723941 | 0.83 | MTOR (0.60) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2724957 | 0.82 | CSF1R (0.56) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL2723390 | 0.82 | CSF1R (0.52) | CSF1RKDM4EALDH1A1SMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | CSF1R 2683/4885KDM4E 1541/4885ALDH1A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.